StockData
Atrium Therapeutics, Inc. logo

Atrium Therapeutics, Inc. (RNA) stock

RNANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$6.48+0.05 (+0.78%)

Close on Nov 17, 2026Market cap $110.85MP/E –Yield –

Atrium Therapeutics cash

Cash and short-term investments held at the end of each period.

Atrium Therapeutics's cash was $232.07M at Sep 30, 2026. For fiscal 2025 it was $0.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$0–
FY2024Dec 31, 2024$0–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$232.07M–
Q2 FY2026Jun 30, 2026$263.90M–
Q1 FY2026Mar 31, 2026$267.85M–
Q4 FY2025Dec 31, 2025$0–
Q3 FY2025Sep 30, 2025$0–
Q2 FY2025Jun 30, 2025$0–
Q1 FY2025Mar 31, 2025$0–
Q4 FY2024Dec 31, 2024$0–

More Atrium Therapeutics figures

See a number that looks wrong?